Salivary Gland Malignant Neoplasms

2

Review clinical trials related to Salivary Gland Malignant Neoplasms. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

This proposed study will evaluate the efficacy and safety of preoperative administration Sintilimab combined with nab-paclitaxel and carboplatin in salivary gland malignant neoplasms who are about to undergo surgery. Monoclonal antibodies, such as Sintilimab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will be helpful for comprehensive exploratory characterization of tumor immune microenvironment and circulating immune cells in these patients.

Participants needed: 15
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUpdated: Dec 2, 2022Locations: 1
Eligibility criteria

Patients must have a histologically confirmed diagnosis of salivary gland cancer... [+18]

Is currently participating in or has participated in a study of an investigation... [+15]

Status: Not yet recruiting

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

This proposed study will evaluate the efficacy and safety of preoperative administration Toripalimab combined with nab-paclitaxel and carboplatin in salivary gland malignant neoplasms who are about to undergo surgery.Monoclonal antibodies, such as Toripalimab , may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.This trial will be helpful for comprehensive exploratory characterization of tumor immune microenvironment and circulating immune cells in these patients.

Participants needed: 15
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUpdated: Apr 28, 2021Locations: 1
Eligibility criteria

Patients must have a histologically confirmed diagnosis of salivary gland cancer... [+18]

Is currently participating in or has participated in a study of an investigation... [+15]